Clinical Trial

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2021-05-18; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2021-06-16
Trial Details
NCT Number NCT04893109
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.
Conditions Breast Cancer, HER2-positive Breast Cancer
Enrollment 500 participants
Start Date 2021-06-16
Primary Completion 2026-11-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21